Trial Profile

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LBL-024 (Primary)
Indications Biliary cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nanjing Leads Biolabs

Most Recent Events

04 Jun 2024 Results (as of october 31, 2023, n=162) assessing safety and efficacy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
17 May 2024 Planned number of patients changed from 370 to 396.
17 May 2024 Planned End Date changed from 1 Jan 2025 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com